Cytek Biosciences Inc (CTKB)
Operating profit margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Operating income | US$ in thousands | -20,523 | -27,845 | -1,826 | 6,447 | 13,659 |
| Revenue | US$ in thousands | 200,453 | 193,015 | 164,036 | 127,950 | 92,839 |
| Operating profit margin | -10.24% | -14.43% | -1.11% | 5.04% | 14.71% |
December 31, 2024 calculation
Operating profit margin = Operating income ÷ Revenue
= $-20,523K ÷ $200,453K
= -10.24%
The operating profit margin of Cytek Biosciences Inc has shown a declining trend over the years based on the data provided. In December 31, 2020, the operating profit margin was relatively healthy at 14.71%, indicating that the company was able to efficiently generate profits from its core operations. However, there was a significant decrease in the operating profit margin to 5.04% by December 31, 2021, signaling a potential decrease in operational efficiency.
The trend continued to deteriorate as the operating profit margin declined to -1.11% by December 31, 2022, indicating that the company's operating expenses might have exceeded its operating income. This negative trend persisted into the following years, with operating profit margins of -14.43% in 2023 and -10.24% in 2024.
Overall, the decreasing trend in Cytek Biosciences Inc's operating profit margin highlights potential challenges in managing operational costs relative to revenue generation. It suggests a need for the company to review and optimize its cost structure and operational processes to improve profitability and sustain long-term financial health.
Peer comparison
Dec 31, 2024